Annual report 2012
Today Vitrolife is publishing the Annual Report for 2012 in Swedish. The Annual Report is attached to this press release and will also be available on www.vitrolife.com.
The printed version of the Annual Report will be distributed by mail during the week commencing 15 April. It will be distributed to Nordic shareholders who are new from last year and to remaining shareholders who have requested that the annual report should be sent to them.
The printed version of the Annual Report can be ordered on the company's website www.vitrolife.com, by phone +46 (0)31 721 80 00 or by email email@example.com.
April 4, 2013
VITROLIFE AB (publ)
Queries should be addressed to:
Mikael Engblom, CFO, tel 46 31 721 80 14
Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on April 4, 2013 at 17:00 p.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
Vitrolife is a global medical device Group. Vitrolife Fertility product area develops, produces and markets products for the treatment of human infertility. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes
Vitrolife has approximately 230 employees and the company's products are sold in almost 100 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China, Japan and Hungary. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: firstname.lastname@example.org. Website: www.vitrolife.com/